BriaCell Therapeutics Announces Pricing of Public Offering
PHILADELPHIA and VANCOUVER, British Columbia, Feb. 03, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care,
BriaCell Therapeutics (NASDAQ:BCTX) Price Target Raised to $32.00
BriaCell Therapeutics (NASDAQ:BCTX – Get Free Report) had its price target lifted by investment analysts at HC Wainwright from $15.00 to $32.00 in a research note issued to investors on Monday,Benzinga reports.
Biomednewsbreaks - Briacell Therapeutics Corp. (NASDAQ: BCTX) (TSX: BCT) Announces Pricing Of $3.05M Public Offering
BriaCell (NASDAQ: BCTX, BCTXW) (TSX: BCT) , a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, has
BriaCell Therapeutics Announces Proposed Public Offering of Common Shares
PHILADELPHIA and VANCOUVER, British Columbia, Feb. 03, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care,
BriaCell Therapeutics Shares Hit Record Low After Public Offering News
Shares of BriaCell Therapeutics were trading at all-time lows in Monday's after-hours market, following news the company plans to sell shares in a best-efforts public offering.
BriaCell announces public offering of common shares
PHILADELPHIA and VANCOUVER, British Columbia - BriaCell Therapeutics Corp., a clinical-stage biotechnology company specializing in immunotherapies for cancer care, announced today its plans to conduct a best-efforts public offering of common shares.
BriaCell announces common stock offering, no amount given
Therapeutics announced that it intends to offer to sell common shares in a best-efforts public offering. ThinkEquity is acting
H.C. Wainwright raises Briacell stock target to $32 on trial success
H.C. Wainwright analyst Emily Bodnar increased the price target for Briacell Therapeutics (NASDAQ:BCTX) to $32 from the previous $15, while maintaining a Buy rating on the stock. The company, ...
BriaCell Announces Resolution of Lung Metastasis in First Patient treated with Bria-OTS™
Lung metastasis (from metastatic breast cancer) resolved - after only 2 months (4 doses) of treatment with Bria-OTS™ ...
Nasdaq8d
BriaCell Announces Completion of 15:1 Share Consolidation
PHILADELPHIA and VANCOUVER, British Columbia, Jan. 27, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the ...
BriaCell Therapeutics股票因积极的临床试验结果上涨
Investing.com -- BriaCell Therapeutics Corp. (NASDAQ: BCTX ...
BriaCell 762.5K share Spot Secondary priced at $4.00
The deal priced below last closing price of $5.04. ThinkEquity is acting as sole book running manager for the offering.Maximize Your ...